SpringWorks Therapeutics: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
SpringWorks Therapeutics (NASDAQ:SWTX) reported Q4 earnings with an EPS of $-1.45, missing estimates by -17.0%. Revenue increased by $5.45 million from the previous year. Despite beating EPS estimates last quarter, the share price dropped by 4.0% the following day.
February 27, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
SpringWorks Therapeutics reported a Q4 EPS of $-1.45, missing estimates by -17.0%, with revenue up $5.45 million YOY. Last quarter's EPS beat was followed by a 4.0% share price drop.
Missing earnings estimates by a significant margin (-17.0%) typically has a negative impact on investor sentiment and stock price in the short term. The historical context of a share price drop following last quarter's earnings beat despite surpassing EPS estimates suggests a potentially heightened sensitivity of SWTX's stock price to earnings performance.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100